Spectral AI’s (MDAI) “Buy” Rating Reaffirmed at HC Wainwright

Spectral AI (NASDAQ:MDAI)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $3.50 price target on the stock. HC Wainwright’s price target indicates a potential upside of 98.86% from the stock’s current price.

Spectral AI Price Performance

Shares of NASDAQ MDAI opened at $1.76 on Tuesday. Spectral AI has a 1 year low of $0.82 and a 1 year high of $3.25. The firm has a market cap of $32.71 million, a PE ratio of -2.71 and a beta of 0.43. The company has a 50 day simple moving average of $1.89 and a 200 day simple moving average of $1.67.

Hedge Funds Weigh In On Spectral AI

Hedge funds have recently modified their holdings of the business. Virtu Financial LLC bought a new position in Spectral AI during the 4th quarter worth $38,000. Northern Trust Corp bought a new stake in shares of Spectral AI in the 4th quarter valued at about $44,000. Millington Financial Advisors LLC acquired a new stake in shares of Spectral AI in the fourth quarter valued at about $85,000. Jane Street Group LLC bought a new position in shares of Spectral AI during the fourth quarter worth about $92,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Spectral AI in the fourth quarter worth approximately $272,000. Institutional investors and hedge funds own 67.08% of the company’s stock.

About Spectral AI

Spectral AI, Inc, an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers.